[1]柯雨欣,刘星,张萌,等.茯苓多糖调控SREBP1信号通路改善非酒精性脂肪肝大鼠肝脏脂质沉积的作用机制[J].陕西中医,2026,(4):467-471.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.006]
　KE Yuxin,LIU Xing,ZHANG Meng,et al.Study on the effect of Poria cocos polysaccharides regulating the SREBP1 signaling pathway on improving hepatic lipid deposition in non-alcoholic fatty liver disease rats[J].,2026,(4):467-471.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.006]
点击复制

茯苓多糖调控SREBP1信号通路改善非酒精性脂肪肝大鼠肝脏脂质沉积的作用机制

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
467-471
栏目:
基础研究
出版日期:
2026-04-05

文章信息/Info

Title:
Study on the effect of Poria cocos polysaccharides regulating the SREBP1 signaling pathway on improving hepatic lipid deposition in non-alcoholic fatty liver disease rats
作者:
柯雨欣1; 刘星1; 张萌2; 李源源1; 禹红1; 喻灿3
（1.武汉市中医医院检验科，湖北 武汉 430050；2.湖北省中医院内分泌病科，湖北 武汉 430061；3.武汉市中医医院急诊科，湖北 武汉 430050）
Author(s):
KE Yuxin1; LIU Xing1; ZHANG Meng2; LI Yuanyuan1; YU Hong1; YU Can3
（1.Department of Laboratory Medicine,Wuhan Hospital of Traditional Chinese Medicine,Wuhan 430050，China;2.Department of Endocrinology,Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China;3.Department of Emergency Medicine,Wuhan Hospital of Traditional Chinese Medicine,Wuhan 430050，China)
关键词:
茯苓多糖; 非酒精性脂肪肝; 大鼠; 脂质沉积; 总胆固醇; 甘油三酯; 低密度脂蛋白胆固醇
Keywords:
Poria cocos polysaccharide; Non alcoholic fatty liver; Rats; Lipid deposition; Total cholesterol; Triglyceride; Low-density lipoprotein cholesterol
分类号:
R 575
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.006
文献标志码:
A
摘要:
目的：研究分析茯苓多糖（PCP）调控SREBP1信号通路对非酒精性脂肪肝（NAFLD）大鼠肝脏脂质沉积的影响。方法：SFP雄性SD大鼠60只，随机分为对照组、模型组、低剂量组、高剂量组（100、300 mg/kg）,喂养6周高脂饲料建立NAFLD模型。模型组灌胃蒸馏水，低剂量组、高剂量组大鼠灌胃不同剂量PCP，连续给药8周，处死并取出大鼠肝脏组织，体外进行HepG2细胞培养，游离脂肪酸诱导NAFLD细胞模型，低剂量组和高剂量组加入不同浓度的茯苓多糖培养24 h。检测各组大鼠血脂、抗氧化应激指标，行细胞油红O染色。荧光定量PCR检测各组大鼠肝组织中固醇调节元件结合蛋白1（SREBP1）、脂肪酸合酶（FASN）、硬脂酰辅酶A去饱和酶1（SCD1）的表达。结果：与对照组比较，模型组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、丙二醛(MDA)表达水平升高（均P<0.05），模型组HDL-C、SOD、GSH-Px水平、SREBP1信号通路相关蛋白表达降低（均P<0.05）。与模型组、低剂量组比较，高剂量组TG、TC、LDL-C、MDA水平下降，HDL-C、SOD、GSH-Px水平升高（均P<0.05）。油红O染色后，模型组比对照组细胞内红色脂滴的数量增多，与模型组比较，低剂量组、高剂量组细胞内红色脂滴数量减少（P<0.05）。结论：茯苓多糖能够降低肝脏内脂质积累，改善血脂水平，可有效改善体内氧化应激反应，其作用机制为调节SREBP1脂质合成相关信号通路。
Abstract:
Objective:To investigate and analyze the effect of Poria cocos polysaccharides (PCP) regulating the SREBP1 signaling pathway on hepatic lipid deposition in non-alcoholic fatty liver disease (NAFLD) rats.Methods:A high-fat diet was used to establish a NAFLD rat model in 60 rats,randomly divided into control group,model group,low and high dose groups.Establish a NAFLD model with high-fat diet and feed it for 6 weeks.The model group was given distilled water by gavage,while the low-dose and high-dose groups of rats were given different doses of PCP by gavage for 8 consecutive weeks.Rats were euthanized and their liver tissues were taken out for HepG2 cell culture in vitro.Free fatty acid induced NAFLD cell models were established,and the low-dose and high-dose groups were cultured in different concentrations of Poria cocos polysaccharides for 24 hours.Blood lipids and antioxidant stress indicators were detected in each group of rats,and cell oil red O staining was performed.Fluorescence quantitative PCR was used to detect the expression of SREBP1,FASN,and SCD1 in liver tissues of each group.Results:Compared with the control group,the expression levels of TC,TG,LDL-C,MDA in the model group were increased (all P<0.05),while the levels of HDL-C,SOD,GSH-Px,and SREBP1 signaling in the model group were decreased (all P<0.05).Compared with the model group and the low-dose group,the levels of TG,TC,LDL-C,and MDA in the high-dose group were decreased,and the levels of HDL-C,SOD,and GSH-Px were increased (all P<0.05).After Oil Red O staining,the number of red lipid droplets in the cells of the model group was larger than that in the control group.Compared with the model group,the number of red lipid droplets in the cells of the low-dose group and the high-dose group was decreased (P<0.05).Conclusion:Poria cocos polysaccharides can reduce lipid accumulation in the liver,improve blood lipid levels,and effectively improve oxidative stress response in the body.Its mechanism of action is to regulate the SREBP1 lipid synthesis related signaling pathway.

参考文献/References:

[1]孟志超,周林,刘毓玲.茯苓多糖对非酒精性脂肪肝相关肝细胞癌小鼠肠道菌群、肝功能的影响[J].联勤军事医学,2025,39(1):11-15.
[2]张文彤,姜丽,房文洁,等.葛根芩连汤对胰岛素抵抗大鼠肝脏能量代谢及游离脂肪酸的影响[J].中药新药与临床药理,2024,35(5):615-622.
[3]张岩岩.天麻素通过AMPK信号通路改善非酒精性脂肪性肝病[D].武汉:华中农业大学，2022.
[4]高飞,钟辉云,陈可禧,等.大黄有效组分“大黄酸-大黄素”联合治疗溃疡性结肠炎作用机制研究[J].中国中药杂志,2022,47(15):4148-4155.
[5]郭永宁.刘淑玲.蔡海荣.等.疏肝温胆汤联合常规西药治疗代谢综合征临床研究[J].新中医,2022,54(7):84-88.
[6]郑兰兰，郭才，何燕芳，等.铁死亡在中药治疗肝纤维化中的研究进展[J].中国实验方剂学杂志，2023，29(23)：235-244.
[7]曹慧敏,孔亮,隋国媛,等.苓桂术甘汤对非酒精性脂肪肝相关肝细胞癌模型小鼠肝脂肪酸代谢重编程的影响[J].中医杂志,2023,64(13):1366-1374.
[8]杨帆,李娟,何昉,等.利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响[J].陕西中医,2023,44(10):1404-1407.
[9]海杰，陈振东，张宗博，等.中医药防治脂肪性肝病的历史沿革与研究现状[J].中医药临床杂志,2024,36(5):994-1001.
[10]李艳娟,张美,李艳芹,等.茯苓及其复方抗糖脂代谢紊乱的研究进展[J].上海中医药大学学报,2024,38(1):89-100.
[11]张孟莲,张耀文,唐林峰,等.天麻素通过调节SREBP1c信号通路抑制非酒精性脂肪肝[J].中国实验方剂学杂志,2024,30(11):70-77.
[12]张远哲,黎豫川,蔡琨,等.六味降脂汤对非酒精性脂肪肝大鼠氧化应激及AMPK/ACC/CPT1A通路的影响及作用机制研究[J].时珍国医国药,2024,35(4):853-858.
[13]许国超,马向明.苦杏仁苷调节SIRT1/LKB1/AMPK信号通路对非酒精性脂肪肝大鼠纤维化的影响及其作用机制[J].中国老年学杂志,2025,45(5):1140-1145.
[14]董文娟,杨立宏,张文佳.降脂瘦身汤对非酒精性脂肪肝大鼠脂代谢及核转录因子-B蛋白表达影响的实验研究[J].陕西中医,2021,42(8):1016-1019.
[15]彭伟航,张为章,黄小燕,等.疏肝温胆汤对代谢综合征小鼠胰岛素抵抗及肝脏脂质沉积的影响及机制[J].中药新药与临床药理,2025,26(8):1243-1248.
[16]杨林泉,乔莉,朱慧明,等.利拉鲁肽调控Cideb通路改善肝脏脂质沉积的作用研究[J].中国药学杂志，2025,60(15):1577-1586.
[17]黎珊珊,区岛良,张梅，等.大黄酚通过核因子E2相关因子2/血红素氧合酶-1信号通路对糖尿病足溃疡大鼠新生血管生成及氧化应激的影响[J].陕西医学杂志,2023,52(12):1660-1664.
[18]王希文,贺琼,杜凡，等.大黄酸通过Sirt1/AMPK信号通路对非酒精性脂肪性肝病小鼠肝功能及肝细胞脂代谢的影响[J].中西医结合肝病杂志,2023,33(11):1000-1006.
[19]张猛,陈晹,刘娇,等.非酒精性脂肪性肝病小鼠肝组织与脂质代谢相关基因 FASN、ACC1和SREBP1c水平分析[J].实用肝脏病杂志,2020,2(32):163-166.
[20]张付民，罗政，周炎涛，等.二陈汤对肥胖小鼠肝脏脂代谢及AMPK/ACC/SREBP1信号通路作用机制研究[J].中西医结合肝病杂志,2023,33(6):525-529,535.
[21]钟庆玲,李良平.肠道菌群和色氨酸代谢在非酒精性脂肪性肝病中的作用[J].临床肝胆病杂志,2022,38(6):1411-1415.
[22]于雷,孙超,张曼旭.灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用[J].实用肝脏病杂志,2021,24(4):476-479.
[23]杨灿,王玥,孙伟泽,等.肝功能异常乙型肝炎孕妇孕早期血清IL-1、IL-12及IFN-α水平变化及预测价值分析[J].国际检验医学杂志,2024,45(14):1710-1714,1719.
[24]葛仁斌,罗倩,施丽萍,等.基于 mDixon-Quant技术对非酒精性脂肪性胰病的磁共振成像诊断研究[J].华南国防医学杂志,2022,36(2):109-113.
[25]马熙淼,饶卉明,綦 鹏,等.基于MAPK/PPAR-γ通路探讨柴胡桂枝汤对非酒精性脂肪肝大鼠脂代谢的影响[J].武警后勤学院学报(医学版),2021,30(8):1-6.

相似文献/References:

[1]樊橡伟,胡 勃,王向阳△.肝苏胶囊联合水飞蓟宾胶囊治疗非酒精性脂肪肝合并慢性乙肝临床研究*[J].陕西中医,2019,(2):160.
　FAN Xiangwei,HU Bo,WANG Xiangyang..The efficacy of Gansu capsules combined with Silibinin capsules in the treatment of Nonalcoholic fatty liver disease and chronic hepatitis B[J].,2019,(4):160.
[2]杨斯皓,马方霞,詹 云.一贯煎合六味地黄汤配合西药治疗2型糖尿病合并非酒精性脂肪肝临床疗效及对患者生活质量的评价*[J].陕西中医,2019,(8):1006.
　YANG Sihao,MA Fangxia,ZHAN Yun..Clinical efficacy and quality of life evaluation of Yiguanjian plus Liuwei Dihuang decoction with western medicine in the treatment of type 2 diabetes with nonalcoholic fatty liver disease[J].,2019,(4):1006.
[3]蔡媛媛,蔡 敏△,程亚伟.蔡敏教授运用调肝一方治疗非酒精性脂肪肝经验总结*[J].陕西中医,2019,(9):1275.
[4]王开霞,郑 超,朱晓骏,等.茵陈五苓散治疗胆汁淤积研究进展*[J].陕西中医,2019,(12):1822.
[5]李 莎,寇少杰,薛敬东.薛敬东运用“浊毒理论”治疗非酒精性脂肪肝经验总结[J].陕西中医,2021,(3):363.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.025]
[6]董文娟,杨立宏,张文佳.降脂瘦身汤对非酒精性脂肪肝大鼠脂代谢及核转录因子-κB蛋白表达影响的实验研究[J].陕西中医,2021,(8):1016.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.007]
　DONG Wenjuan,YANG Lihong,ZHANG Wenjia.Study of Jiangzhi Shoushen decoction on lipid metabolism and NF-κB protein expression with nonalcoholic fatty liver rats[J].,2021,(4):1016.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.007]
[7]宋 丽,石 蕊,赵香君.手足十二针联合加味茵陈蒿汤治疗非酒精性脂肪肝及对患者肠道菌群的影响[J].陕西中医,2022,(2):252.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.027]
　SONG Li,SHI Rui,ZHAO Xiangjun.Effect of hand foot twelve needles combined with modified Yinchenhao decoction on intestinal flora of patients with nonalcoholic fatty liver disease[J].,2022,(4):252.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.027]
[8]杨 帆,魏小果,李 娟,等.清肝降脂汤对体外诱导非酒精性脂肪肝细胞模型脂代谢和过氧化物酶体增殖物激活受体-α的调节作用研究[J].陕西中医,2024,(10):1326.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.006]
　YANG Fan,WEI Xiaoguo,LI Juan,et al.The regulatory effect of Qinggan Jiangzhi decoction on lipid metabolism and PPAR-α in non-alcoholic fatty liver cell model induced in vitro[J].,2024,(4):1326.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.006]
[9]黄桢奇,周艳林,柯婷,等.中药治疗2型糖尿病合并非酒精性脂肪性肝病作用机制进展[J].陕西中医,2025,46(10):1437.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.028]
　HUANG Zhenqi,ZHOU Yanlin,KE Ting,et al.Research progress on the mechanism of traditional chinese medicine in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease[J].,2025,46(4):1437.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.028]

备注/Memo

备注/Memo:
湖北省自然科学基金资助项目（2020CFB631）；湖北省中医药管理局中医药科研项目（ZY2023F052）
更新日期/Last Update: 2026-04-05